CSTONE PHARMA-B2616.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, CSTONE PHARMA-B (2616.HK) trades at a negative P/E (-16.46x, due to a recent net loss), P/B of 5.30x, P/S of 16.40x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 56th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/S sits at the 66th percentile over the trailing 10Y window (vs. 57th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 79th percentile within its industry and the 90th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.27%, ranking at the 99th percentile over the trailing 20Y window.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. CSTONE PHARMA-B operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2616 · SEHK: 2616 · 2616
Want the full picture on whether CSTONE PHARMA-B (2616.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -16.46 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 5.30 | ||||||
| P/S (TTM) | 16.40 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.27% |